MAXIMUM STANDARDIZED UPTAKE VALUE CUTOFF POINT OF THE LYMPH NODES METASTASES IN NSCLC DETECTED BY FDG-PET/CT A PROGNOSTIC VALUE

Similar documents
Utility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC)

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW

Risk Factors for Occult Mediastinal Metastases in Clinical Stage I Non-Small Cell Lung Cancer

The right middle lobe is the smallest lobe in the lung, and

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis

Dr Sneha Shah Tata Memorial Hospital, Mumbai.

Utility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer

FDG PET-CT in Non-small Cell Lung Cancer: Relationship between Primary Tumor FDG Uptake and Extensional or Metastatic Potential

PET/CT in lung cancer

Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010

Evaluation of Lung Cancer Response: Current Practice and Advances

Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer

S taging non-small lung cancer (NSCLC) is an important

Noninvasive Differential Diagnosis of Pulmonary Nodules Using the Standardized Uptake Value Index

Unusual False-Positive Mesenteric Lymph Nodes Detected by PET/CT in a Metastatic Survey of Lung Cancer

The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology

Patients with pathologically diagnosed involved mediastinal

Lung cancer is a major cause of cancer deaths worldwide.

Triage of Limited Versus Extensive Disease on 18 F-FDG PET/CT Scan in Small Cell lung Cancer

Do we need a new SUVmax threshold value for the evaluation of mediastinal lymph nodes?

Research Article The Advantage of PET and CT Integration in Examination of Lung Tumors

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09

LYMPHATIC DRAINAGE IN THE HEAD & NECK

Mediastinal Staging. Samer Kanaan, M.D.

FDG-PET/CT in Gynaecologic Cancers

FDG-PET/CT imaging for mediastinal staging in patients with potentially resectable non-small cell lung cancer.

PET CT for Staging Lung Cancer

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China

Recent advances in positron emission tomography (PET)

Role of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City

PET/CT in breast cancer staging

Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD

Yuehong Wang 1, Shanni Ma 1, Mengjie Dong 2, Yake Yao 1, Kanfeng Liu 2 and Jianying Zhou 1*

Omission of Mediastinal Lymph Node Dissection in Lung Cancer: Its Techniques and Diagnostic Procedures

Does Positron Emission Tomography Prevent Nontherapeutic Pulmonary Resections for Clinical Stage IA Lung Cancer?

Case presentation. Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium

Imaging in gastric cancer

Usefulness of Delayed Scan of FDG PET for the Diagnosis of Lymph Node Metastasis in Non-Small Cell Lung Cancer

Radiological staging of lung cancer. Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Small cell lung cancer (SCLC), which represents 20%

Bilateral hilar 18 F-FDG avid foci are often noted on

The accurate assessment of lymph node involvement is

Radiology Pathology Conference

Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer

Anthony J. Paravati 1, David W. Johnstone 2, Marc A. Seltzer 3, Candice A. Johnstone 4. Introduction

Positron emission tomography predicts survival in malignant pleural mesothelioma

FDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave

Lung Cancer Staging: The Revised TNM Classification

MEDIASTINAL STAGING surgical pro

ROLE OF PET-CT SCAN IN LOCALLY ADVANCED HEAD & NECK CANCER: A Prospective Study

Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP

Original Article Clinical predictors of lymph node metastasis in lung adenocarcinoma: an exploratory study

Aldo Carnevale 1, Gianluca Milanese 2,3, Nicola Sverzellati 2, Mario Silva 2,3

The Role of PET / CT in Lung Cancer Staging

Esophageal Cancer Initially Thought to be Accompanied by a Solitary Metastasis to an Intrathoracic Paraaortic Lymph Node

Lung Cancer Update. HARMESH R NAIK, MD. February 28, 2001

An Update: Lung Cancer

In non small cell lung cancer, metastasis to lymph nodes, the N factor, is

Diffuse high-attenuation within mediastinal lymph nodes on non-enhanced CT scan: Usefulness in the prediction of benignancy

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis

systematic mediastinal lymph node

Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer

Prognostic value of visceral pleura invasion in non-small cell lung cancer q

Positron emission tomography/computer tomography in the evaluation of head and neck cancer treatment

RESEARCH. 145 February 2015, Vol. 105, No. 2

Predictive risk factors for lymph node metastasis in patients with resected nonsmall cell lung cancer: a case control study

Positron Emission Tomography in Lung Cancer

PET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET

PULMONARY PERFUSION SCINTIGRAPHY AND SURVIVAL IN LUNG CARCINOMA PATIENTS TREATED WITH CHEMOTHERAPY AND RADIOTHERAPY

Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer

ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD

North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer

Patients with stage IIIa non-small cell lung cancer

Imaging of Pulmonary Tuberculosis with 18 F-Fluoro-Deoxy-Glucose and

Multifocal Lung Cancer

Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer

Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer

Cheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda

Potential clinical value of PET/CT in predicting occult nodal metastasis in T1-T2N0M0 lung cancer patients staged by PET/CT

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival

Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Hong-Yao Xu *, Sheng-Xi Wu, He-San Luo, Chu-Yun Chen, Lian-Xing Lin and He-Cheng Huang

Predictors of unexpected nodal upstaging in patients with ct1-3n0 non-small cell lung cancer (NSCLC) submitted to thoracoscopic lobectomy

Maximum Standard Uptake Value of Mediastinal Lymph Nodes on Integrated FDG-PET-CT Predicts Pathology in Patients with Non-Small Cell Lung Cancer

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG

Although the international TNM classification system

Chirurgie beim oligo-metastatischen NSCLC

Early and locally advanced non-small-cell lung cancer (NSCLC)

EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI

Variability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival

Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis

The tumor, node, metastasis (TNM) staging system of lung

WHAT DOES PET IMAGING ADD TO CONVENTIONAL STAGING OF HEAD AND NECK CANCER PATIENTS?

Transcription:

Page 1 from 8

MAXIMUM STANDARDIZED UPTAKE VALUE CUTOFF POINT OF THE LYMPH NODES METASTASES IN NSCLC DETECTED BY FDG-PET/CT A PROGNOSTIC VALUE Nina Georgieva 1, Zhivka Dancheva 2, Pavel Bochev 2, Borislav Chaushev 2, Aneliya Klisarova 2, Katya Peeva 3 1 Department of Physics, Biophysics, Roentgenology and Radiology, Medical Faculty, Trakia University, Stara Zagora, Bulgaria 2 Department of Nuclear Medicine and Radiotherapy St. Marina University Hospital, Varna, Bulgaria 3 Department of Social Medicine and Health Management, Medical Faculty, Trakia University, Abstract: Stara Zagora, Bulgaria Aim: To determine the prognostic diagnostic value of the increased lymph nodes SUVmax in NSCLC patients and its relation to their survival. Materials and Methods: We studied 73 pretreatment patients with NSCLC using 18 FDG-РЕТ/СТ. There were 53 men (72,6%) and 20 women (27,4%), in the range of 18-79 years old. Increased pathologic SUVmax was detected in 184 lymph nodes. Patients were staged according to TNM and final diagnosis registered in Bulgarian National Cancer Registry (BNCR). Disease beginning in the BNCR was considered either the date of registration or the operation date. Patients who presented with NSCLC between July 2009 and July 2012 were included in 18 FDG-РЕТ/СТ pre-treatment examination and survival was followed-up until April 2014. The distribution in BNCR according to N was as follows: 18 patients had N0 (24,7%), 10 had N1 (13,7%), 21 had N2 (28,8%), 11 had N3 (15,1%) and 13 patients had Nx (17,8%). The correlations between the primary tumor s SUVmax and the lymph nodes SUVmax were evaluated by Spearman correlation coefficient. A cutoff point was defined through the logrank test and the Wilcoxon test. Survival analysis was performed by use of the Kaplan-Meier method. The test for comparing the equality of the survival distributions between the study groups was done by use of the Mantel-Cox Log Rank, with an inclusion criterion of a P value less than 0,05. Results: Between the primary tumor SUVmax and the lymph nodes SUVmax there was statistically significant (Р<0,05) positive weak correlation (r=0,297). Between the lymph nodes SUVmax and the survival there was statistically significant (Р=0,0001) moderate inverse correlation (r=-0,311). At cutoff point equal to 4,5 for the lymph nodes SUVmax, the following NSCLC patients survival rate was estimated in months: for SUVmax<4,5, Mean=23,1, Median=16,8; for SUVmax 4,5, Mean=10,5, Median=7,1. The studied factor lymph nodes SUVmax was considered as a dichotomous variable. It influenced statistically significant the survival of the NSCLC patients (Р=0,0001). Statistically significant correlation was not established between the survival, the presence of lymph nodes with increased SUVmax and the histology of the primary tumor. Conclusion: The survival of the NSCLC patients is significantly dependent on the regional lymph nodes SUVmax before treatment. Regional lymph nodes SUVmax before treatment over 4,5 is a cutoff point which defines risk for worse survival and in operable patients it implies additional treatment options after the surgical intervention. Page 2 from 8

Introduction Lymph nodes SUVmax is a possible prognostic factor in NSCLC, discussed by different authors. The aim of the current paper is to determine the prognostic diagnostic value of the increase of SUVmax in lymph nodes in NSCLC patients and its relation to their survival. Subjects and Methods We studied 73 pre-treatment patients with NSCLC using 18 FDG-РЕТ/СТ. There were 53 men (72,6%) and 20 women (27,4%), in the range of 18-79 years. The examinations were performed by use of the Phillips Gemini TF apparatus, manufactured in 2009, combining 16 slice CT and PET in 3D regimen with an ability for Time-of-Flight registrations. 18 F-Fluorodesoxyglucosae (FDG) was injected i.v. through a previously applied peripheral venous catheter with activity of 5,18 MBq/kg. The patients were examined after a minimum of 6 hours without any food intake meanwhile or intake of alkaloid or sweet beverages, and without cigarette smoking or chewing-gum use in the same period. The patients signed an informed consent. The blood glucose was tested on site. After the injection, the patients were left for 60-70 min in a dimmed quiet room and after that they were positioned at the apparatus for scanning. Body PET/CT includes a low dose of CT and PET from the vertex to the middle of the hip, as well as an interactive reconstruction following the standard manufacturer s reconstruction algorithm for whole body scans and with the ability for fusion of the CT images from the examination. Increased pathologic SUVmax was detected in 184 lymph nodes. Patients were staged according to TNM and final diagnosis registered in Bulgarian National Cancer Registry (BNCR). Disease beginning in the BNCR was considered either the date of registration or the operation date. Patients who presented with NSCLC between July 2009 and July 2012 were included in 18 FDG-РЕТ/СТ pre-treatment examination and survival was followed-up until April 2014. The distribution in BNCR according to N was as follows: 18 patients had N0 (24,7%), 10 had N1 (13,7%), 21 had N2 (28,8%), 11 had N3 (15,1%) and 13 patients had Nx (17,8%). The correlations between the primary tumor SUVmax and the lymph nodes SUVmax were evaluated by Spearman s correlation coefficient. A cutoff point was defined through the log-rank test and the Wilcoxon test. Survival analysis was performed by use of the Kaplan-Meier method. The test for comparing the equality of the survival distributions between the study groups was done by use of the Mantel-Cox Log Rank, with an inclusion criterion of a P value less than 0,05. All statistical analysis was performed with the IBM SPSS Statistics 19 software. Results Reactive lymph nodes were defined as those having increased size and not increased SUVmax; or increased SUVmax, independent of the size, but histopathologically without tumor cell findings (with anthracosis, sinus histiocytosis, chronic lymphadenitis). We identified 21 lymph nodes as reactive lymph nodes with SUVmax from 1,6 to 4,5. The reactive lymph nodes SUVmax has Mean=2,8, SD=0,9 SE=0,2, and 95% CI (2,4; 3,2). We found in 17 nodes one dimension increased from 8 mm to 14,5mm Mean = 11,7 mm, SE= 0,5, 95%CI (10,7; 12,8); in 7 nodes we found two dimensions increased from 5 mm to13 mm Mean = 9,6 mm, SE = 1,1, 95%CI (7; 12,2). PET/CT before treatment of a 71-year-old patient with a final diagnosis: left superior lobe pulmonary carcinoma, T2N1M0 IIB stage is presented on Fig.1. Histologic result: differentiated Page 3 from 8

squamous cell carcinoma G2. PET/CT detected a lesion in segment III of the left lung with dimensions of 37,2mm/21,2mm and SUVmax 3,6, hilar lymph nodes, sub-carinal lymph nodes, prevascular lymph nodes with SUVmax of 3,8-4,1, engagement of cervical-jugular lymph nodes, submandibular lymph nodes, axillar lymph nodes, para-aortal iliac lymph nodes, inguinal lymph nodes with increased uptake primary carcinoma of the lungs with increased metabolic activity in all lymph chains. Intra-operatively a tumor formation in the upper lobe of segment III was found with dimensions 0,8cm/3cm. An upper left lobectomy with systemic mediastinal lymph dissection was performed. Histologic result: moderately differentiated squamous cell carcinoma with extensive necrosis, chronic unspecific lymphadenitis of the hilar and mediastinal lymph nodes. Fig. 1. PET/CT fusion and PET before treatment of a male patient, 71 year old. Metastatic lymph nodes were defined based on their increased SUVmax value, independent of the size; or with histologically verified metastases. In the defined as metastatic lymph nodes size 1 is from 5 mm to 62 mm, Mean = 16,6 mm, SE = 0,98 95%CI (14,7; 18,6), size 2 is from 7,3 mm to 52 mm, Mean = 19,8 mm, SE = 2,9, 95%CI (13,7; 25,9). The SUVmax of the metastatic lymph nodes is Mean=6, SD=2,9, SE=0,2, and 95% CI (5,5; 6,5). РЕТ/СТ before treatment of a 48 years old female patient is presented on Fig. 2. The final diagnosis was right pulmonary carcinoma T2N2M0, IIIA stage. State after lobectomy and chemotherapy. Histologic result: Squamous cell non-keratinocyte carcinoma. A soft-tissue lesion was detected by PET/CT in segment VI of the right lung with dimensions 25,6 mm/22 mm, SUVmax 20,2 and a single lower para-tracheal lymph node with diameter 11,8 mm, SUVmax 13,4 primary carcinoma of the right lung with metastatic lymph node. Page 4 from 8

Fig.2. РЕТ/СТ- fusion in transversal projection of a 48 year old woman with lung carcinoma in IIIA stage before treatment. The relation between primary tumor SUVmax and lymph nodes SUVmax we have evaluated by the correlation coefficient of Spearman (in testing the normality of distribution of the variables survival of the patients in months and lymph nodes SUVmax is found that they do not have normal distribution, but the variable primary tumor SUVmax has normal distribution, which is the reason we use the correlation coefficient of Spearman). Between the primary tumor SUVmax and the lymph nodes SUVmax there was statistically significant (Р<0,05) positive weak correlation (r=0,297). Between the lymph nodes SUVmax and the survival there was statistically significant (Р<0,0001) moderate inverse correlation (r=-0,311). We use SUVmax as binary variable with borderline (Cutoff) point, defined through log-rank test and Wilcoxon test. At cutoff point equal to 4,5 for the lymph nodes SUVmax, the following NSCLC patients survival rate was estimated in months: for SUVmax<4,5, Mean=23,1, Median=16,8; for SUVmax 4,5, Mean=10,5, Median=7,1. The studied lymph nodes SUVmax factor was considered as a dichotomous variable. It had statistically significant influence on the survival of the NSCLC patients (Р<0,0001). On Fig. 2 is shown the graph for survival in relation to SUVmax of the lymph nodes. Fig. 2. Survival of the patients with NSCLC of the lung before treatment, with SUVmax of the lymph nodes below and over 4,5. Page 5 from 8

Statistically significant correlation was not established between the survival, the presence of lymph nodes with increased SUVmax and the histology of the primary tumor. Discussion Lymph nodes SUVmax is discussed as prognostic factor from different authors. Lymph nodes SUVmax less than 8 is a single prognostic factor for a progression free survival, free of distant metastases and overall survival of patients in III stage of NSCLC(1). The ratio between pretherapeutic lymph nodes SUVmax and tumor SUVmax over 0,9 together with performance state identifies the group with increased risk for death after radiotherapy (2). At ratio between pretherapeutic lymph nodes SUVmax and tumor SUVmax 0,56 and more there is 94% probability for malignant lymph node (3). А tumor/lymph node SUVmax ratio lower than 5 predicts the metastasis to lymph nodes with a high sensitivity (4). The value of SUVmax in malignant N2 lymph nodes is cited 4,4 (5), or 5,3 (6, 7). Lymph nodes metastasis are not detected in lung cancer when tumor SUVmax is less than 2,5, while in lung cancer with a tumor SUVmax more than 12 there is a 70% probability of lymph nodes metastasis. The likelihood of lymph nodes metastasis increases together with the primary tumor SUVmax increase (8). SUVmax is not a discriminant between minimal and extensive lymph nodes involvement in the malignant process (9). The patients without FDG uptake in the N2 lymph nodes after operation have better survival than the patients with FDG uptake in N2 lymph nodes (10). FDG uptake by the primary tumor may be an independent predictor of regional lymph node metastasis in patients with NSCLC (11, 12, 13, 14, 15). Another author does not find correlation between FDG uptake by the primary tumor and the metastases in the lymph nodes (16). PET is superior to CT in staging for lung cancer, yet it cannot detect metastatic focuses in the lymph nodes less than 4mm (17). Falsely positive lymph nodes are found to be due to granulomatous infection and silicosis (18) or due to reactive lymphadenitis (17). In lymph nodes defined as reactive in current study and among the falsely positive lymph nodes the histologic findings were of sinus histiocytosis, anthracosis, follicular hyperplasia and chronic lymphadenitis. The results from the current study find relation between the primary tumor SUVmax and the lymph nodes SUVmax; and between lymph nodes SUVmax and the patient survival. These relations are statistically significant (P<0,05). SUVmax over 4,5 defines the group of patients with increased risk for worse survival. Conclusion The survival of the NSCLC patients is significantly dependent on the regional lymph nodes SUVmax before treatment. Regional lymph nodes SUVmax before treatment over 4,5 is a cutoff point which defines a risk for worse survival and in operable patients it requires additional treatment procedures after the surgical intervention. Page 6 from 8

Reference: 1. Lee.V.H., Chan W.W. Lee E.Y. et al. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy. Am J Clin Oncol 2014, Apr 5.(Epub ahead of print). 2. Kang H-C., Wu H-G., Yu T. Et al. Fluorodeoxydlucose positron-emission tomography ratio in non-small cell lung cancer patients treated with definitive radiotherapy. Radiat Oncol J 2013; 31: 3: 111-117. 3. Cerfolio R.J., Bryant A.S. Ratio of the Maximum Standardized Uptake Value on FDG-PET of the Mediastinal (N2) Lymph Nodes to the Primary Tumor May Be a Universal Predictor of Nodal Malignancy in Patients With Nonsmall-Cell Lung Cancer. Ann Thorac Surg 2007; 83: 1826-1830. 4. Koksal D., Demirag F., Bayiz H. et al. The correlation of SUVmax with pathological characteristics of primary tumor and the value of Tumor/Lymph node SUVmax ratio for predicting metastasis to lymph nodes in resected NSCLC patients. Journal of Cardiothoracic Surgery 2013: 8: 63. 5. Vansteenkiste J.F., Stroobans S.G., De Leyn P.R. et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J. Clin. Oncol.1998; 16: 6: 2142-2149. 6. Bryant A.S., Cerfolio R.J., Klemm K.M. Ojha B. Maximum Standard Uptake Value of Mediastinal Lymph Nodes on Integrated FDG-PET-CT Predicts Pathology in Patients with Non- Small Cell Lung Cancer. Ann Thorac Surg 2006; 82: 417-423. 7. Lee B.E., Redwine J., Foster C. et al. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3. J Thorac Cardiovsc Surg 2008; 135: 3: 111-117. 8. Nambu A., Kato S., Sato Y. et al. Relationship between maximum standardized uptake value (SUVmax) of lung cancer and lymph node metastasis on FDG-PET. Ann. Nucl. Med. 2009: 23 (3): 269-275. 9. Muto J., Hida Y., Kaga K. et al. Use of Maximum Standardized Uptake Value on Fluorodeoxyglucose Positron-emission Tomography in Predicting Lymph Node Involvement in Patients with Primary Non-small Cell Lung Cancer. Anticancer Research 2014: 34: 805-810. 10. Barnett S., Baste J.M., Murugappan K. et al. Long-term survival of 42 patients with resected N2 non-small-cell lung cancer: the impact of 2-(18)F-fluoro-2-deoxy-D-glucose positron emission tomogram mediastinal staging. Eur J Cardiothorac Surg 2011; 39: 1: 96-101. 11. Li M., Wu N., Zheng R., Liang Y. et al. Primary tumor PET/CT [ 18 F]FDG uptake is an independent predictive factor for regional lymph node metastasis in patients with non-small cell lung cancer. Cancer Imaging. 2012; 12: 3: 566-572. 12. Miyasaka Y., Suzuki K., Takamochi K. et al. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumor is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer. Eur. J Cardio-Thoracic Surg. 2013: 44: 83-87. Page 7 from 8

13. Zhu S-H., Zhang Y., Yu Y-H. et al. FDG PET-CT in Non-small Cell Lung Cancer: Relationship between Primary Tumor FDG Uptake and Extensional or Metastatic Potential. Asian Pacific J Cancer Prev. 2013: 14: 5: 2925-2929. 14. Li X., Zhang H., Xing L. et al. Predictive value of primary fluorine-18 fluorordeoxyglucose standard uptake value for a better choice of systematic nodal dissection or sampling in clinical stage ia non-small-cell lung cancer. Clin Lung Cancer 2013: 14 (5): 568-73. 15. Maeda R., Isowa N., Onuma H. et al. The maximum standardized 18 F-fluorodeoxyglucose uptake on positron emisión tomography predict lymph node metastasis and invasiveness in clinical stage IA non-small cell lung cancer. Interactive CardioVascular and Thoracic Surgery 2009: 9: 79-82. 16. Özgül M., Kirkil G., Seyhan E. Et al. The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer. Multidisciplinary Respiratory Medicine 2013, 8: 69. 17. Nomori H., Watanabe K., Ohtsuka T. et al. The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer. J Thorac Cardiovasc Surg 2004; 127: 1087-92. 18. Gupta N.C., Tamim W.J., Craeber G.G. et al. Mediastinal Lymph Node Sampling Following Positron Emission Tomography With Fluorodeoxyglucose Imaging in Lung Cancer Staging. Chest 2001; 120: 521-527. Page 8 from 8